Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02301117 · ClinicalTrials.gov registry record · Phase 1

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

A Phase 1 study of Advanced Solid Tumors, sponsored by Taiho Oncology.

Completed
Registry status
Phase 1
Development phase
43
Enrollment target
14
Study locations

NCT02301117: Completed Phase 1 study of Advanced Solid Tumors, sponsored by Taiho Oncology.

NCT02301117 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Taiho Oncology. The registered enrollment target is 43 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (78% lower). The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02301117, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Taiho Oncology.

COMPLETED
Registry status
Phase 1
Development phase
43 participants
Enrollment target
14
Study locations

Study Summary

Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.

Primary Outcome

FTD, FTY and TPI: pharmacokinetic parameters Cmax, Tmax, AUC0-last, AUC0-inf, and T1/2. FTD, FTY, and TPI: Ae% and CLr. FTD and TPI: CL/F, Vd/F of TAS-102

Conditions Studied

Interventions

  • DRUG TAS-102

Study Locations (14)

Other

  • Brno Clinical Site - Brno
  • Praha Clinical Site - Prague
  • Belgrade Clinical Site - Belgrade
  • Sremska Kamenica Clinical Site - Kamenitz

California

  • Duarte Clinical Site - Duarte
  • Santa Monica Clinical Site - Santa Monica

Ohio

  • Cleveland Clinical Site - Cleveland
  • Cleveland Clinical Site - Cleveland

Arizona

  • Phoenix Clinical Site - Phoenix

Florida

  • Gainesville Clinical Site - Gainesville

Maryland

  • Baltimore Clinical Site - Baltimore

Massachusetts

  • Boston Clinical Site - Boston

Pennsylvania

  • Pittsburgh Clinical Site - Pittsburgh

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2015-01
Est. Completion 2019-06-19
Phase Phase 1
Taiho Oncology

52 total trials

What the finished NCT02301117 record still lists

NCT02301117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which TAS-102 is the first listed.

NCT02301117 lists 14 locations in 9 states (Other, California, Ohio).

Frequently Asked Questions

What is clinical trial NCT02301117 about?

NCT02301117 is a clinical study titled "A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment". Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.

What is the current status of trial NCT02301117?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2015-01. Estimated completion is 2019-06-19.

What conditions does trial NCT02301117 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT02301117?

The interventions under investigation include: TAS-102 (DRUG).

Who is sponsoring clinical trial NCT02301117?

This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02301117 being conducted?

This trial has 14 study locations across Arizona, California, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02301117's enrollment target sits among peer trials

43 108th of 144 higher than 37 of 144 other Advanced Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02301117, the US trial registry maintained by the National Library of Medicine. NCT02301117 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.